GlassScriptPhysician profile
David S Chua
NPI 1023268646
$1,383.16
in general payments reported to CMS, 2019-2025
24 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $152 · 2021: $116 · 2022: $197 · 2023: $213 · 2024: $277 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $190.52 | 2021-2025 | |
| Astellas Pharma US INC | $136.84 | 2023-2025 | Veozah, Myrbetriq |
| Mallinckrodt Enterprises LLC | $124.33 | 2019 | |
| Lilly USA, LLC | $119.50 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $111.22 | 2019-2024 | Evenity, Prolia |
| Mallinckrodt Hospital Products INC. | $94.99 | 2020 | |
| Mylan Specialty L.P. | $82.47 | 2022-2024 | Yupelri, Yupelri |
| Pfizer INC. | $73.42 | 2022-2023 | |
| Novo Nordisk INC | $66.34 | 2019-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $42.05 | 2019-2020 | |
| Vifor Pharma, INC. | $38.18 | 2019 | |
| Calliditas Therapeutics US INC. | $38.13 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $29.41 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.91 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $27.89 | 2023 | Minimed 780g, Minimed 770g |
| Otsuka America Pharmaceutical, INC. | $26.12 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.10 | 2025 | Caplyta |
| Exact Sciences Corporation | $18.80 | 2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $18.35 | 2021 | |
| Mimedx Group, INC. | $17.38 | 2024 | |
| Viatris Specialty LLC | $16.82 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $16.08 | 2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.